Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

Follow-on Biologics in the News - No. 3

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Donald Zuhn -- Johnson & Johnson: 5-Year Exclusivity Period Would Kill Incentives to Innovate Last month, Amgen Inc. Vice President Stuart Watt asserted that any follow-on biologics regulatory pathway established by Congress would have to specify an exclusivity period of at least 12 years in order to provide incentives to innovator drug companies to continue developing new biologic drugs (see "Amgen VP Makes Case for Longer Exclusivity Period in Follow-on Biologics Legislation"). On the heels of Mr. Watt's statement, Johnson & Johnson executive director for biotechnology policy Audrey Philips recently indicated that Congress should provide for a 14-year exclusivity...

Full post as published by Patent Docs on April 28, 2009 (boomark / email).